REFERENCES
1. Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203-22.
2. Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293-313.
3. Zeng X, Liao G, Li S, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. Hepatology. 2023;77:1122-38.
4. Wang Z, Liu M, Zhang DZ, et al. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022;76:66-77.
5. Huang Z, Guo Z, Ni J, et al. Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤ 5 cm: incidence, risk factors and clinical significance. Int J Hyperthermia. 2021;38:1164-73.
6. Shi ZR, Duan YX, Cui F, et al. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation. J Exp Clin Cancer Res. 2023;42:133.
7. Abdel-Moety A, Baddour N, Salem P, El-Tobgy H, El-Shendidi A. SQSTM1 expression in hepatocellular carcinoma and relation to tumor recurrence after radiofrequency ablation. J Clin Exp Hepatol. 2022;12:774-84.
8. Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58:1667-80.
9. Cui R, Wang L, Zhang D, et al. Combination therapy using microwave ablation and d-mannose-chelated iron oxide nanoparticles inhibits hepatocellular carcinoma progression. Acta Pharm Sin B. 2022;12:3475-85.
10. Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421.
11. Puijk RS, Dijkstra M, van der Lei S, et al. The added value of transcatheter CT hepatic angiography (CTHA) image guidance in percutaneous thermal liver ablation: an experts’ opinion pictorial essay. Cancers. 2024;16:1193.
12. Huang Q, Zeng Q, Long Y, et al. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma - a prospective randomized controlled trial. Int J Hyperthermia. 2019;36:1207-15.
13. Qi X, Yang M, Ma L, et al. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. J Immunother Cancer. 2020;8:e001038.
14. Li M, Jiang A, Han H, et al. A trinity nano-vaccine system with spatiotemporal immune effect for the adjuvant cancer therapy after radiofrequency ablation. ACS Nano. 2024;18:4590-612.
15. Ao F, Li X, Tan Y, et al. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment. J Control Release. 2024;369:296-308.
16. Li X, Zhang Y, Li S, et al. Macrophage hitchhiking for systematic suppression in postablative multifocal HCC. Hepatology. 2025;81:44-59.
17. Wu CY, Lin LY, Lee TY, et al. Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis. Int J Surg. 2024;110:7234-44.
18. Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20:4160-6.
19. Yang Y, Chen Y, Ye F, et al. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol. 2021;31:3053-64.
20. Ke S, Ding XM, Kong J, et al. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med. 2010;8:73.
21. Imajo K, Ogawa Y, Yoneda M, Saito S, Nakajima A. A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma. J Med Ultrason. 2020;47:265-77.
22. Tan J, Tang T, Zhao W, Zhang ZS, Xiao YD. Initial incomplete thermal ablation is associated with a high risk of tumor progression in patients with hepatocellular carcinoma. Front Oncol. 2021;11:760173.
23. Bigos KJ, Quiles CG, Lunj S, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front Oncol. 2024;14:1331355.
24. Hernandez GA, Perera RM. Autophagy in cancer cell remodeling and quality control. Mol Cell. 2022;82:1514-27.
25. Wang X, Deng Q, Feng K, et al. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop. Oncol Rep. 2018;40:241-51.
26. Jondal DE, Thompson SM, Butters KA, et al. Heat stress and hepatic laser thermal ablation induce hepatocellular carcinoma growth: role of PI3K/mTOR/AKT signaling. Radiology. 2018;288:730-8.
27. Jiang J, Chen S, Li K, et al. Targeting autophagy enhances heat stress-induced apoptosis via the ATP-AMPK-mTOR axis for hepatocellular carcinoma. Int J Hyperthermia. 2019;36:499-510.
28. Xu WL, Wang SH, Sun WB, et al. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway. BMB Rep. 2019;52:277-82.
29. Yu ZJ, Guo SW, Wang BS, et al. Ruthenium complex suppresses proliferation of residual hepatocellular carcinoma after incomplete radiofrequency ablation therapy. Recent Pat Anticancer Drug Discov. 2024;Epub ahead of print.
30. Iwahashi S, Shimada M, Utsunomiya T, et al. Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation. Cancer Lett. 2016;375:47-50.
31. Zhang N, Wang L, Chai ZT, et al. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One. 2014;9:e115949.
32. Zhang N, Li H, Qin C, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019;145:895-907.
33. Zhu S, Wu Y, Zhang X, et al. Targeting N7-methylguanosine tRNA modification blocks hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Mol Ther. 2023;31:1596-614.
34. Tong Y, Yang H, Xu X, et al. Effect of a hypoxic microenvironment after radiofrequency ablation on residual hepatocellular cell migration and invasion. Cancer Sci. 2017;108:753-62.
35. Ortmann BM, Taylor CT, Rocha S. Hypoxia research, where to now? Trends Biochem Sci. 2024;49:573-82.
36. Li K, Niu Y, Yuan Y, et al. Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-β signaling. Oncogene. 2022;41:3197-209.
37. Kong J, Kong J, Pan B, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA. PLoS One. 2012;7:e37266.
38. Xiang S, Li J, Zhang M. TGF-β1 inhibitor enhances the therapeutic effect of microwave ablation on hepatocellular carcinoma. Int J Hyperthermia. 2024;41:2359496.
39. Chen Y, Bei J, Chen M, et al. Intratumoral lactate depletion based on injectable nanoparticles-hydrogel composite system synergizes with immunotherapy against postablative hepatocellular carcinoma recurrence. Adv Healthc Mater. 2024;13:e2303031.
40. Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013;57:1448-57.
41. Collettini F, Brangsch J, Reimann C, et al. Hepatic radiofrequency ablation: monitoring of ablation-induced macrophage recruitment in the periablational rim using SPION-enhanced macrophage-specific magnetic resonance imaging. Invest Radiol. 2021;56:591-8.
42. Liu X, Zhang W, Xu Y, et al. Targeting PI3Kγ/AKT pathway remodels LC3-associated phagocytosis induced immunosuppression after radiofrequency ablation. Adv Sci. 2022;9:e2102182.
43. Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5:209-16.
44. Bansal S, Gui J, Merrill C, Wong JK, Burak KW, Wilson SR. Contrast-enhanced US in local ablative therapy and secondary surveillance for hepatocellular carcinoma. Radiographics. 2019;39:1302-22.
45. Fite BZ, Wang J, Ghanouni P, Ferrara KW. A review of imaging methods to assess ultrasound-mediated ablation. BME Front. 2022;2022:9758652.
46. Shyn PB, Casadaban LC, Sainani NI, et al. Intraprocedural ablation margin assessment by using ammonia perfusion PET during FDG PET/CT-guided liver tumor ablation: a pilot study. Radiology. 2018;288:138-45.
47. Jiang Q, Zeng Y, Xu Y, et al. Ultrasound molecular imaging as a potential non-invasive diagnosis to detect the margin of hepatocarcinoma via CSF-1R targeting. Front Bioeng Biotechnol. 2020;8:783.
48. Kan X, Zhou G, Zhang F, et al. Interventional optical imaging permits instant visualization of pathological zones of ablated tumor periphery and residual tumor detection. Cancer Res. 2021;81:4594-602.
49. Mateva G, Handzhiev S, Kostadinova I. The role of 18F-FDG PET/CT in evaluating the efficacy of radiofrequency ablation in metastatic and primary liver tumors: preliminary results. Mol Imaging Radionucl Ther. 2021;30:1-7.
50. Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.
51. Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev. 2022;1:CD013345.
52. Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 2018;38:61.
53. Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074-81.
54. Guo B, Chen Q, Liu Z, Chen X, Zhu P. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Front Oncol. 2023;13:1098958.
55. Horkan C, Dalal K, Coderre JA, et al. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology. 2005;235:81-8.
56. Young S, Golzarian J. Locoregional therapies in the treatment of 3- to 5-cm hepatocellular carcinoma: critical review of the literature. AJR Am J Roentgenol. 2020;215:223-34.
57. Hendriks P, Rietbergen DDD, van Erkel AR, et al; Dutch Hepatocellular and Cholangiocarcinoma Group. Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial). Eur J Nucl Med Mol Imaging. 2024;51:2085-97.
58. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383-91.e6.
59. Su JY, Li JR, Pan LX, et al. Tertiary lymphoid structures in HCC: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy. Hepatology. 2025;Epub ahead of print.
60. Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia. 2021;38:1519-28.
61. Chow P, Chen M, Cheng A, et al. Abstract CT003: IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Cancer Research. 2023;83:CT003.
62. Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599-611.
63. Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21:294-311.
64. Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019;7:322.
65. Chen S, Shen B, Wu Y, et al. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. Int Immunopharmacol. 2023;119:110228.
66. Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014;109:1891-9.
67. Bruix J, Takayama T, Mazzaferro V, et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-54.
68. Chen X, Huang Y, Chen H, et al. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression. J Nanobiotechnology. 2022;20:34.
69. Xiao Z, Li T, Zheng X, et al. Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation. Bioact Mater. 2023;21:57-68.
70. Minami Y, Kudo M. Image guidance in ablation for hepatocellular carcinoma: contrast-enhanced ultrasound and fusion imaging. Front Oncol. 2021;11:593636.
71. Cao SE, Zhang LQ, Kuang SC, et al. Multiphase convolutional dense network for the classification of focal liver lesions on dynamic contrast-enhanced computed tomography. World J Gastroenterol. 2020;26:3660-72.
72. Grazioli L, Ambrosini R, Frittoli B, Grazioli M, Morone M. Primary benign liver lesions. Eur J Radiol. 2017;95:378-98.
73. Bottari A, Silipigni S, Carerj ML, et al. Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis. Radiol Med. 2020;125:7-14.
74. Granata V, Grassi R, Fusco R, et al. Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma. Infect Agent Cancer. 2021;16:53.
75. Mathew RP, Sam M, Raubenheimer M, Patel V, Low G. Hepatic hemangiomas: the various imaging avatars and its mimickers. Radiol Med. 2020;125:801-15.
